Premium
CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA
Author(s) -
Dickinson M.J.,
Morschhauser F.,
Iacoboni G.,
CarloStella C.,
Offner F.C.,
Sureda A.,
Salles G.,
Martinez J.,
Crump M.,
Thomas D.N.,
Morcos P.N.,
Ferlini C.,
Broeske A.,
Bacac M.,
Dimier N.J.,
Umaña P.,
Moore T.,
Weisser M.,
Hutchings M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.59_2629
Subject(s) - medicine , cd20 , cytokine release syndrome , tolerability , gastroenterology , refractory (planetary science) , lymphoma , rituximab , cd8 , oncology , immunology , antigen , adverse effect , immunotherapy , cancer , astrobiology , physics , chimeric antigen receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom